AURA insider transaction filings
Aura Biosciences, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-01. Screen AURA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 7 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Abu-Absi Susan — Chief Operating Officer | 1 | — | — | 2 |
| Bender Jeremy — Director | 1 | — | — | 2 |
| Elazzouzi Amy — SVP, Finance & PAO | 1 | — | — | 2 |
| Hopkins Janet Jill — Chief Medical Officer | 1 | — | — | 2 |
| Kratz Erica — Chief Reg. & Quality Officer | 1 | — | — | 2 |
| Person Julie — Chief People Officer | 1 | — | — | 2 |
| Kilroy Conor — See Remarks | 1 | — | — | 1 |
Recent Form 4 filings — Aura Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-01 | 4 | Person Julie — Chief People Officer | Grant/award (A): 107,611 @ $0 · Grant/award (A): 212,389 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Kratz Erica — Chief Reg. & Quality Officer | Grant/award (A): 100,885 @ $0 · Grant/award (A): 199,115 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Elazzouzi Amy — SVP, Finance & PAO | Grant/award (A): 23,540 @ $0 · Grant/award (A): 46,460 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Hopkins Janet Jill — Chief Medical Officer | Grant/award (A): 58,850 @ $0 · Grant/award (A): 116,150 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Abu-Absi Susan — Chief Operating Officer | Grant/award (A): 134,513 @ $0 · Grant/award (A): 265,487 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Bender Jeremy — Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-07-01 | 4 | Kilroy Conor — See Remarks | Grant/award (A): 14,858 @ $0 | EDGAR |
| 2026-06-16 | 4 | Gibney Anthony S — See Remarks | Sale (S): 12,824 @ $6.42 | EDGAR |
| 2026-06-15 | 4 | Bitetti Teresa Marie — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Srivastava Sapna — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Johnson David Michael — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Mattessich Antony C. — Director | Grant/award (A): 15,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Holles Natalie C. — See Remarks, Director | Grant/award (A): 600,118 @ $0 · Grant/award (A): 553,844 @ $0 · Grant/award (A): 2,169,103 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Matrix Capital Management Company, LP — 10% owner GOEL DAVID E. — 10% owner | Sale (S): 6,922,870 @ $5.64 | EDGAR |
| 2026-04-16 | 4 | Kilroy Conor — See Remarks | Sale (S): 11,738 @ $7.02 | EDGAR |
| 2026-03-03 | 4 | Kilroy Conor — See Remarks | Grant/award (A): 62,339 @ $0 · Grant/award (A): 112,661 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Gibney Anthony S — See Remarks | Grant/award (A): 71,245 @ $0 · Grant/award (A): 128,755 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | de los Pinos Elisabet — See Remarks, Director | Grant/award (A): 166,000 @ $0 · Grant/award (A): 249,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Plavsic Mark — Chief Technology Officer | Grant/award (A): 62,339 @ $0 · Grant/award (A): 112,661 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Hopkins Janet Jill — Chief Medical Officer | Grant/award (A): 89,056 @ $0 · Grant/award (A): 160,944 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Elazzouzi Amy — Senior Vice President, Finance | Grant/award (A): 44,528 @ $0 · Grant/award (A): 80,472 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Kilroy Conor — See Remarks | Sale (S): 12,079 @ $5.05 | EDGAR |
| 2026-02-17 | 4 | Plavsic Mark — Chief Technology Officer | Sale (S): 15,890 @ $5.05 | EDGAR |
| 2026-02-17 | 4 | Hopkins Janet Jill — Chief Medical Officer | Sale (S): 20,401 @ $5.06 | EDGAR |
| 2026-02-17 | 4 | Elazzouzi Amy — Senior Vice President, Finance | Sale (S): 8,549 @ $5.06 | EDGAR |
| 2026-02-17 | 4 | de los Pinos Elisabet — See Remarks, Director | Sale (S): 47,648 @ $5.06 | EDGAR |
| 2026-01-20 | 4 | Elazzouzi Amy — Senior Vice President, Finance | Sale (S): 1,581 @ $4.86 | EDGAR |
| 2026-01-20 | 4 | de los Pinos Elisabet — See Remarks, Director | Sale (S): 16,928 @ $4.86 | EDGAR |
| 2025-11-17 | 4 | Hopkins Janet Jill — Chief Medical Officer | Sale (S): 17,109 @ $5.42 | EDGAR |
| 2025-10-29 | 4 | Elazzouzi Amy — Senior Vice President, Finance | Sale (S): 896 @ $6.35 | EDGAR |
| 2025-10-29 | 4 | de los Pinos Elisabet — See Remarks, Director | Sale (S): 9,049 @ $6.35 | EDGAR |
| 2025-10-16 | 4 | Plavsic Mark — Chief Technology Officer | Sale (S): 12,169 @ $6.35 | EDGAR |
| 2025-08-18 | 4 | Elazzouzi Amy — Senior Vice President, Finance | Option exercise (M): 2,554 @ $5.07 · Option exercise (M): 1,094 @ $5.48 · Option exercise (M): 547 @ $5.48 · Option exercise (M): 547 @ $5.21 · Option exercise (M): 4,744 @ $2.74 · Option exercise (M): 1,094 @ $3.16 · +9 more | EDGAR |
| 2025-06-18 | 4 | Srivastava Sapna — Director | Grant/award (A): 13,000 @ $0 · Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Johnson David Michael — Director | Grant/award (A): 13,000 @ $0 · Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Mattessich Antony C. — Director | Grant/award (A): 13,000 @ $0 · Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Gibney Anthony S — See Remarks | Grant/award (A): 150,000 @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | de los Pinos Elisabet — See Remarks, Director | Option exercise (M): 10,948 @ $5.07 · Tax withholding (F): 9,948 @ $6.16 · Option exercise (M): 10,948 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Johnson David Michael — Director | Purchase (P): 20,000 @ $4.90 · Purchase (P): 5,000 (derivative) | EDGAR |
| 2025-05-20 | 4 | Gibney Anthony S — See Remarks | Purchase (P): 50,000 @ $4.90 · Sale (S): 1,519 @ $5.15 · Purchase (P): 12,500 (derivative) | EDGAR |
| 2025-04-16 | 4 | Elazzouzi Amy — Senior Vice President, Finance | Sale (S): 897 @ $5.49 | EDGAR |
| 2025-04-16 | 4 | Kilroy Conor — See Remarks | Sale (S): 7,162 @ $5.49 | EDGAR |
| 2025-04-02 | 4 | Bitetti Teresa Marie — Director | Grant/award (A): 21,000 @ $0 · Grant/award (A): 29,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Plavsic Mark — Chief Technology Officer | Sale (S): 2,151 @ $7.75 | EDGAR |
| 2025-02-18 | 4 | Elazzouzi Amy — Senior Vice President, Finance | Sale (S): 1,404 @ $7.75 | EDGAR |
| 2025-02-18 | 4 | Hopkins Janet Jill — Chief Medical Officer | Sale (S): 2,534 @ $7.75 | EDGAR |
| 2025-02-18 | 4 | de los Pinos Elisabet — See Remarks, Director | Sale (S): 20,221 @ $7.75 | EDGAR |
| 2025-02-04 | 4 | Hopkins Janet Jill — Chief Medical Officer | Grant/award (A): 120,635 @ $0 · Grant/award (A): 79,365 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Kilroy Conor — See Remarks | Grant/award (A): 90,475 @ $0 · Grant/award (A): 59,525 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Elazzouzi Amy — Senior Vice President, Finance | Grant/award (A): 45,240 @ $0 · Grant/award (A): 29,760 (derivative) @ $0 | EDGAR |
Recent 8-K events — Aura Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-07-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 8.01 — Other Events | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AURA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →